// App-Quantinova.ai

: VENETOCLAX AND NAVITOCLAX IN RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AND LYMPHOBLASTIC LYMPHOMA

Researchers

Presenter

  • Elias Jabbour

Principal Investigators

  • Norman J. Lacayo

  • Ashish Bajel

  • Jeffrey Rubnitz

  • Jessica Leonard

  • Charles G. Mullighan

  • Seong Lin Khaw

  • Susan I. Colace

  • Joseph T. Opferman

  • Robin Norris

  • Kathryn Roberts

  • Mohamed Badawi

  • Michelle Schmidt

  • Bo Tong

  • Lang Zhou

  • Jeremy A. Ross

  • Lindsey Rosenwinkel

  • Amanda Jacobson

  • Wendy Stock

  • Thomas Alexander

Medical Centers

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • City of Hope, Duarte, United States

  • VA Palo Alto HCS/ Stanford University, Palo Alto, California, United States

  • Royal Melbourne Hospital, Melbourne, Australia

  • St Jude Childrens Research Hospital, Memphis, TN, United States

  • Oregon Health and Science University, Portland, Oregon, United States

  • Royal Children's Hospital, Melbourne, Victoria, Australia

  • Nationwide Childrens Hospital/Dept. of Anes., Columbus, Ohio, United States

  • Cincinnati Children's Hospital Medical Center, Cincinnati, OH

  • AbbVie Inc., North Chicago, Illinois, United States

  • University of Chicago, Chicago, IL, United States

  • Department of Epidemiology, University of North Carolina, Chapel Hill, NC, United States

Locations

  • United States

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Lymphomas

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • PEG-asparaginase

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Asparaginase

  • Vincristine

  • Navitoclax

  • Venetoclax

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT03181126

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved